New NHS landscape looks attractive to UK industry
This article was originally published in Clinica
The Eurozone woes had to share equal news billing in the UK yesterday with another issue that has both vexed and perplexed in equal measure. That is: how to get the best out of the NHS infrastructure and deliver high-quality healthcare while maximising the business opportunities for locally-based healthcare companies. The latter’s fortunes are usually inextricably linked with those of the NHS.
You may also be interested in...
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.